» Articles » PMID: 39764559

Loading of CAR-T Cells with Magnetic Nanoparticles for Controlled Targeting Suppresses Inflammatory Cytokine Release and Switches Tumor Cell Death Mechanism

Abstract

Therapies against hematological malignancies using chimeric antigen receptors (CAR)-T cells have shown great potential; however, therapeutic success in solid tumors has been constrained due to limited tumor trafficking and infiltration, as well as the scarcity of cancer-specific solid tumor antigens. Therefore, the enrichment of tumor-antigen specific CAR-T cells in the desired region is critical for improving therapy efficacy and reducing systemic on-target/off-tumor side effects. Here, we functionalized human CAR-T cells with superparamagnetic iron oxide nanoparticles (SPIONs), making them magnetically controllable for site-directed targeting. SPION-loaded CAR-T cells maintained their specific cytolytic capacity against melanoma cells expressing the CAR-specific antigen chondroitin sulfate proteoglycan (CSPG4). Importantly, SPIONs suppressed cytokine release in the loaded CAR-T cells, shifting the cell death phenotype in the tumor cells from pyroptosis to apoptosis. Furthermore, SPION-loaded CAR-T cells could be enriched in a dynamic flow model through an external magnetic field and be detected in MRI. These results demonstrate that lytic cytotoxicity is retained after SPION-functionalization and provides a basis for future site-specific immunotherapies against solid tumors with reduced systemic adverse side effects.

References
1.
Challier J, Carbillon L, Kacemi A, Vervelle C, Bintein T, GALTIER M . Characterization of first trimester human fetal placental vessels using immunocytochemical markers. Cell Mol Biol (Noisy-le-grand). 2002; 47 Online Pub:OL79-87. View

2.
Rodriguez-Marquez P, Calleja-Cervantes M, Serrano G, Oliver-Caldes A, Palacios-Berraquero M, Martin-Mallo A . CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. Sci Adv. 2022; 8(39):eabo0514. PMC: 9524842. DOI: 10.1126/sciadv.abo0514. View

3.
Levine B, Miskin J, Wonnacott K, Keir C . Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2017; 4:92-101. PMC: 5363291. DOI: 10.1016/j.omtm.2016.12.006. View

4.
Chen X, He W, Hu L, Li J, Fang Y, Wang X . Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 2016; 26(9):1007-20. PMC: 5034106. DOI: 10.1038/cr.2016.100. View

5.
Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y . Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020; 368(6494). DOI: 10.1126/science.aaz7548. View